tradingkey.logo

Beyond Air Inc

XAIR

2.230USD

-0.060-2.62%
Close 09/19, 16:00ETQuotes delayed by 15 min
523.30KMarket Cap
LossP/E TTM

Beyond Air Inc

2.230

-0.060-2.62%

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
112 / 207
Overall Ranking
254 / 4720
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 5 analysts
Buy
Current Rating
11.200
Target Price
+389.08%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Beyond Air, Inc. is a commercial stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received United States Food and Drug Administration (FDA) approval for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. It is advancing its other LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19), and nontuberculous mycobacteria (NTM) among others. It has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder (ASD) and other neurological disorders. Its approved product and active pipeline of product candidates include LungFit PH, LungFit PRO and LungFit GO.
Growing
The company is in a growing phase, with the latest annual income totaling USD 3.71M.
Overvalued
The company’s latest PE is -0.06, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 1.63M shares, decreasing 16.44% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 72.59K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.87.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 5.95, which is lower than the Healthcare Equipment & Supplies industry's average of 7.32. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 1.76M, representing a year-over-year increase of 157.69%, while its net profit experienced a year-over-year increase of 36.96%.

Score

Industry at a Glance

Previous score
5.95
Change
0

Financials

5.91

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data

Quality of Earnings

7.00

Operational Efficiency

2.77

Growth Potential

6.97

Shareholder Returns

7.09

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Healthcare Equipment & Supplies industry's average of 3.59. Its current P/E ratio is -0.06, which is 491.45% below the recent high of -0.35 and -2683.25% above the recent low of -1.63.

Score

Industry at a Glance

Previous score
2.80
Change
1.2

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 112/207
No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.00, which is higher than the Healthcare Equipment & Supplies industry's average of 7.70. The average price target for Beyond Air Inc is 12.00, with a high of 14.00 and a low of 5.00.

Score

Industry at a Glance

Previous score
8.00
Change
0

Support & Resistance

No Data

Analyst Rating

Based on 5 analysts
Buy
Current Rating
11.200
Target Price
+402.24%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

118
Total
7
Median
8
Average
Company name
Ratings
Analysts
Beyond Air Inc
XAIR
5
Medtronic PLC
MDT
35
Stryker Corp
SYK
33
Abbott Laboratories
ABT
31
Zimmer Biomet Holdings Inc
ZBH
30
Dexcom Inc
DXCM
29
1
2
3
...
24

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 6.67, which is lower than the Healthcare Equipment & Supplies industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 4.04 and the support level at 1.28, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
6.67
Change
-0.08

Support & Resistance

No Data

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(1)
Neutral(3)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-0.040
Neutral
RSI(14)
46.659
Neutral
STOCH(KDJ)(9,3,3)
9.415
Oversold
ATR(14)
0.395
High Vlolatility
CCI(14)
-54.000
Neutral
Williams %R
95.678
Oversold
TRIX(12,20)
-0.183
Sell
StochRSI(14)
0.000
Oversold
Moving Average
Sell(4)
Neutral(0)
Buy(2)
Indicators
Value
Direction
MA5
2.330
Sell
MA10
2.445
Sell
MA20
2.340
Sell
MA50
2.622
Sell
MA100
1.407
Buy
MA200
0.875
Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Healthcare Equipment & Supplies industry's average of 6.89. The latest institutional shareholding proportion is 34.44%, representing a quarter-over-quarter decrease of 4.02%. The largest institutional shareholder is The Vanguard, holding a total of 72.59K shares, representing 1.35% of shares outstanding, with 20.46% decrease in holdings.

Score

Industry at a Glance

Previous score
3.00
Change
0

Institutional Shareholding

No Data

Shareholder Activity

Name
Shares Held
Chg %
Carey (Robert F.)
5.55M
--
Lisi (Steven A)
3.32M
+2.22%
Balyasny Asset Management LP
3.33M
--
Mosseri Marlio (Charles)
3.22M
+39.30%
Avenue Capital Group
1.64M
-41.30%
The Vanguard Group, Inc.
Star Investors
1.26M
--
Kingdon Capital Management, L.L.C.
936.68K
+65.05%
Geode Capital Management, L.L.C.
825.72K
+46.74%
Bleichroeder LP
738.31K
--
BlackRock Institutional Trust Company, N.A.
540.97K
-0.39%
1
2

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.05, which is lower than the Healthcare Equipment & Supplies industry's average of 3.87. The company's beta value is 0.28. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Score

Industry at a Glance

Previous score
3.05
Change
0
Beta vs S&P 500 index
0.28
VaR
+7.98%
240-Day Maximum Drawdown
+76.01%
240-Day Volatility
+338.65%
Return
Best Daily Return
60 days
+1667.09%
120 days
+1667.09%
5 years
+1667.09%
Worst Daily Return
60 days
-23.26%
120 days
-29.02%
5 years
-51.54%
Sharpe Ratio
60 days
+2.01
120 days
+1.41
5 years
+0.42
Risk Assessment
Maximum Drawdown
240 days
+76.01%
3 years
+97.88%
5 years
+98.98%
Return-to-Drawdown Ratio
240 days
+7.71
3 years
-0.22
5 years
-0.12
Skewness
240 days
+15.39
3 years
+26.39
5 years
+33.80
Volatility
Realised Volatility
240 days
+338.65%
5 years
+174.13%
Standardised True Range
240 days
+4.36%
5 years
+15.53%
Downside Risk-Adjusted Return
120 days
+3729.04%
240 days
+3729.04%
Maximum Daily Upside Volatility
60 days
+4182.44%
Maximum Daily Downside Volatility
60 days
+3249.33%
Liquidity
Average Turnover Rate
60 days
+2.77%
120 days
+2.77%
5 years
--
Turnover Deviation
20 days
-86.77%
60 days
+58.89%
120 days
+58.96%

Peer Comparison

Healthcare Equipment & Supplies
Beyond Air Inc
Beyond Air Inc
XAIR
5.61 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Insulet Corp
Insulet Corp
PODD
8.35 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
STERIS plc
STERIS plc
STE
8.33 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Stevanato Group SpA
Stevanato Group SpA
STVN
8.24 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Abbott Laboratories
Abbott Laboratories
ABT
8.13 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Transmedics Group Inc
Transmedics Group Inc
TMDX
8.01 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI